• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Congress on Coronary Artery Disease >The SHARP Study: Simultaneous Hybrid Revascularization by Carotid Stenting and Coronary Artery Bypass Grafting
【24h】

The SHARP Study: Simultaneous Hybrid Revascularization by Carotid Stenting and Coronary Artery Bypass Grafting

机译：尖锐的研究：颈动脉叉和冠状动脉旁路接枝同时杂交血运重建

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Preventing stroke and cardiovascular events after coronary artery revascularization in patients with elevated surgical risk remains a complex problem. We investigated a new therapeutic strategy consisting of a simultaneous hybrid revascularization by carotid artery stenting (CAS), immediately followed by coronary artery bypass surgery (CABG). One hundred twenty six consecutive patients with severe carotid and coronary artery disease and a standard EuroSCORE > 5 were included in this multicenter study. The primary end point was the incidence of stroke, acute myocardial infarction (AMI) or death at 30 days after CAS-CABG. The rate of procedural success was 98%. The 30-day cumulative incidence of disabling stroke, AMI or death was 3.2%: two patients died (1.6%) in the postoperative period and two patients (1.6%) had a stroke immediately after CAS and before CABG. Three patients died from the 31st day to the 12th month after the procedure. In high risk patients with coronary artery disease suitable for CABG and carotid artery disease, the hybrid revascularization by CAS, immediately followed by CABG is a promising and feasible therapeutic strategy.
机译：在升高外科风险升高的患者冠状动脉血运重建后预防卒中和心血管事件仍然是一个复杂的问题。我们调查了一种新的治疗策略，由颈动脉支架（CAS）同时发生杂交血运重建，紧接着，紧随其后的冠状动脉旁路手术（CABG）。在这项多中心的研究中，包括一百二十六名患有严重颈动脉和冠状动脉疾病的患者和标准欧千岛> 5。主要终点是CAS-CABG后30天在30天内卒中，急性心肌梗死（AMI）或死亡的发生率。程序成功率为98％。 30天累积抚癌，AMI或死亡的发病率为3.2％：两名患者在术后期间死亡（1.6％），两名患者（1.6％）在CAS和CABG之前立即卒中。三名患者从第31天到第12个月后死亡。在适用于CABG和颈动脉疾病的冠状动脉疾病的高风险患者中，CAS的杂交血运重建，紧接着是CABG是一个有前途和可行的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号